Integrating pharmacogenomics into nursing practice implications for clinical decision-making
Keywords:
Pharmacogenomics, Nursing Practice, Clinical Practice Guidelines, Personalized Medicine, ReviewAbstract
Background: Integrating pharmacogenomics (PGx) into nursing practice has the potential to enhance personalized medicine and improve clinical decision-making. Despite its growing relevance, barriers such as insufficient training, limited knowledge, and unclear clinical guidelines hinder the adoption of PGx in nursing. Methods: This study employed a mixed-method systematic review using a convergent integrated approach to explore intrinsic and extrinsic factors influencing nurses' adherence to Clinical Practice Guidelines (CPGs) in PGx. A comprehensive literature search was conducted across multiple databases, synthesizing quantitative and qualitative findings to identify key determinants of adherence. Results: Key intrinsic factors identified include nurses’ baseline knowledge, attitudes, and confidence in applying PGx-related CPGs. Extrinsic factors encompassed institutional support, access to training programs, integration of PGx into electronic health records, and interdisciplinary collaboration. Barriers such as a lack of standardized CPGs and resource limitations were also highlighted. The synthesis revealed that tailored educational interventions and robust support systems significantly improved adherence rates. Furthermore, a strong correlation between interdisciplinary teamwork and effective CPG implementation was noted. Conclusion: Successful integration of pharmacogenomics into nursing practice requires addressing both intrinsic and extrinsic barriers. Strategies such as enhanced education, clear guidelines, and systemic support are essential for fostering adherence to PGx CPGs.
Downloads
References
Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–998. DOI: https://doi.org/10.1592/phco.28.8.992
Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24:656–664. DOI: https://doi.org/10.1007/s11606-009-0949-1
Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013;33:1156–1164. DOI: https://doi.org/10.1002/phar.1329
Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92:87–95. DOI: https://doi.org/10.1038/clpt.2011.371
Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 2013;14:723–726. DOI: https://doi.org/10.2217/pgs.13.59
Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 2014;7:145–162. DOI: https://doi.org/10.2147/PGPM.S63715
Devine EB, Lee C-J, Overby CL, Abernethy N, McCune J, Smith JW, et al. Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach. Int J Med Inform. 2014;83:473–483. DOI: https://doi.org/10.1016/j.ijmedinf.2014.04.008
Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014;34:1102–1112. DOI: https://doi.org/10.1002/phar.1481
Tuteja S, Haynes K, Zayac C, Sprague JE, Bernhardt B, Pyeritz R. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Per Med. 2013;10:793–800. DOI: https://doi.org/10.2217/pme.13.85
De Denus S, Letarte N, Hurlimann T, Lambert J-P, Lavoie A, Robb L, et al. An evaluation of pharmacists’ expectations towards pharmacogenomics. Pharmacogenomics. 2013;14:165–175. DOI: https://doi.org/10.2217/pgs.12.197
Chan TYK, Lee KKC, Critchley JAJH. The needs and sources of drug information among pharmacists in Hong Kong. J Clin Pharm Ther. 1996;21:325–330. DOI: https://doi.org/10.1111/j.1365-2710.1996.tb00026.x
Zehnder S, Beutler M, Bruppacher R, Ehrenhöfer T, Hersberger KE. Needs and use of drug information sources in community pharmacies: a questionnaire based survey in German-speaking Switzerland. Pharm World Sci. 2004;26:197–202. DOI: https://doi.org/10.1023/B:PHAR.0000035881.17853.e0
Wong P-SJ, Ko Y, Sklar GE. Identification and evaluation of pharmacists’ commonly used drug information sources. Ann Pharmacother. 2009;43:347–352. DOI: https://doi.org/10.1345/aph.1L333
Lua H-L, Sklar G, Ko Y. Identification and physicians’ views of their commonly-used drug information sources in Singapore. Int J Clin Pharm. 2011;33:772–778. DOI: https://doi.org/10.1007/s11096-011-9533-y
Kostagiolas PA, Bairaktaris KD, Niakas D. An information behaviour investigation of the community pharmacists in Greece for developing library and information services. Health Info Libr J. 2010;27:46–56. DOI: https://doi.org/10.1111/j.1471-1842.2009.00846.x
Kostagiolas PA, Aggelopoulou VA, Niakas D. A study of the information seeking behaviour of hospital pharmacists: empirical evidence from Greece. Health Info Libr J. 2011;28:302–312. DOI: https://doi.org/10.1111/j.1471-1842.2011.00963.x
Burke W. Genetic Test Evaluation: Information Needs of Clinicians, Policy Makers, and the Public. Am J Epidemiol. 2002;156:311–318. DOI: https://doi.org/10.1093/aje/kwf055
McCullough KB, Formea CM, Berg KD, Burzynski JA, Cunningham JL, Ou NN, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011;75:51. DOI: https://doi.org/10.5688/ajpe75351
Zachariah M, Phansalkar S, Seidling HM, Neri PM, Cresswell KM, Duke J, et al. Development and preliminary evidence for the validity of an instrument assessing implementation of human-factors principles in medication-related decision-support systems--I-MeDeSA. J Am Med Inform Assoc. 2011;18(Suppl 1):i62–i72. DOI: https://doi.org/10.1136/amiajnl-2011-000362
Neri PM, Pollard SE, Volk LA, Newmark LP, Varugheese M, Baxter S, et al. Usability of a novel clinician interface for genetic results. J Biomed Inform. 2012;45:950–957. DOI: https://doi.org/10.1016/j.jbi.2012.03.007
Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. Bioessays. 2000;22:1095–1105. DOI: https://doi.org/10.1002/1521-1878(200012)22:12<1095::AID-BIES7>3.0.CO;2-A
FDA. [accessed March 31, 2015];Genomics - Table of Pharmacogenomic Biomarkers in Drug Labels. n.d.
Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract. 2012;25:417–427. DOI: https://doi.org/10.1177/0897190012448309
Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011;89:924–927. DOI: https://doi.org/10.1038/clpt.2011.18
FDA. Guidance for Industry: Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies. 2011
Vaughan KTL, Scolaro KL, Anksorus HN, Roederer MW. An evaluation of pharmacogenomic information provided by five common drug information resources. J Med Libr Assoc. 2014;102:47–51. DOI: https://doi.org/10.3163/1536-5050.102.1.009
Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89:464–467. DOI: https://doi.org/10.1038/clpt.2010.279
Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209–217. DOI: https://doi.org/10.2174/1389200215666140130124910
Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013;94:207–210. DOI: https://doi.org/10.1038/clpt.2013.59
F Thorn C, E Klein T, B Altman R. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11:501–505. DOI: https://doi.org/10.2217/pgs.10.15
Gong L, Owen RP, Gor W, Altman RB, Klein TE. PharmGKB: an integrated resource of pharmacogenomic data and knowledge. Chapter 14:Unit14.7. Curr Protoc Bioinformatics. 2008 DOI: https://doi.org/10.1002/0471250953.bi1407s23
Altman RB. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet. 2007;39:426. DOI: https://doi.org/10.1038/ng0407-426
Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB, et al. PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res. 2002;30:163–165. DOI: https://doi.org/10.1093/nar/30.1.163
Sangkuhl K, Berlin DS, Altman RB, Klein TE. PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev. 2008;40:539–551. DOI: https://doi.org/10.1080/03602530802413338
Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2001;1:167–170. DOI: https://doi.org/10.1038/sj.tpj.6500035
Hernandez-Boussard T, Whirl-Carrillo M, Hebert JM, Gong L, Owen R, Gong M, et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 2008;36:D913–D918. DOI: https://doi.org/10.1093/nar/gkm1009
Boyce RD, Freimuth RR, Romagnoli KM, Pummer T, Hochheiser H, Empey PE. Toward semantic modeling of pharmacogenomic knowledge for clinical and translational decision support. AMIA Summits Transl Sci Proc. 2013:28–32.
Friedman CP. Evaluation Methods in Biomedical Informatics. 2nd. New York: Springer Science & Business Media; 2006. DOI: https://doi.org/10.1007/0-387-30677-3
Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. vol. 3rd. Los Angeles: SAGE Publications; 2008. DOI: https://doi.org/10.4135/9781452230153
Saldaña J. The Coding Manual for Qualitative Researchers. Los Angeles: SAGE Publications Ltd; 2009.
Owen RP, Klein TE, Altman RB. The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB) Clin Pharmacol Ther. 2007;82:472–475. DOI: https://doi.org/10.1038/sj.clpt.6100332
Lee KC, Ma JD, Kuo GM. Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc. 2003;50:e1–e14. DOI: https://doi.org/10.1331/JAPhA.2010.09124
Boland MR, Rusanov A, So Y, Lopez-Jimenez C, Busacca L, Steinman RC, et al. From expert-derived user needs to user-perceived ease of use and usefulness: a two-phase mixed-methods evaluation framework. J Biomed Inform. 2014;52:141–150. DOI: https://doi.org/10.1016/j.jbi.2013.12.004
George J, Doney A, Palmer CN, Lang CC. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin. Cardiovasc Ther. 2010;28:135–138. DOI: https://doi.org/10.1111/j.1755-5922.2010.00176.x
Romagnoli KM, Boyce RD, Empey PE, Adams S, Hochheiser H. Bringing clinical pharmacogenomics information to pharmacists: a qualitative study of information needs and resource requirements. International journal of medical informatics. 2016 Feb 1;86:54-61. DOI: https://doi.org/10.1016/j.ijmedinf.2015.11.015
Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92:235–242. DOI: https://doi.org/10.1038/clpt.2012.66
Published
How to Cite
Issue
Section
Copyright (c) 2017 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
